PUBLISHER: DelveInsight | PRODUCT CODE: 2167079
PUBLISHER: DelveInsight | PRODUCT CODE: 2167079
DelveInsight's, "Bipolar Disorder (Manic Depression)- Pipeline Insight, 2026" report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in Bipolar Disorder (Manic Depression) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Bipolar Disorder (Manic Depression): Understanding
Bipolar Disorder (Manic Depression): Overview
Bipolar disorder, formerly known as manic depression, is a mental health condition characterized by extreme mood swings that include emotional highs (mania or hypomania) and lows (depression). These mood swings can affect sleep, energy levels, behavior, and the ability to carry out day-to-day tasks. Bipolar disorder is a chronic condition that requires lifelong management. It is classified into several types: Bipolar I, marked by manic episodes lasting at least seven days or by manic symptoms severe enough to require immediate hospital care; Bipolar II, defined by a pattern of depressive episodes and hypomanic episodes, which are less severe than full-blown manic episodes; and Cyclothymic Disorder, characterized by periods of hypomanic and depressive symptoms lasting for at least two years.
The signs and symptoms of bipolar disorder vary depending on whether the person is experiencing mania, hypomania, or depression. During manic episodes, individuals might feel excessively happy, energetic, or irritable, and they may engage in risky behaviors, have racing thoughts, and experience a decreased need for sleep. Hypomania is similar but less intense. Depressive episodes are marked by feelings of sadness, hopelessness, or emptiness, along with fatigue, difficulty concentrating, changes in sleep and appetite, and thoughts of death or suicide. The frequency and intensity of these episodes can vary, with some individuals experiencing rapid cycling between moods. The exact causes of bipolar disorder are not fully understood, but it is believed to result from a combination of genetic, biological, and environmental factors. There is a strong hereditary component; individuals with a family history of bipolar disorder are at higher risk. Biological differences in brain structure and function, as well as imbalances in neurotransmitters, also play a role. Stressful life events and trauma can trigger or worsen episodes of bipolar disorder in susceptible individuals.
Pathophysiologically, bipolar disorder is associated with dysregulation in brain circuits involving the prefrontal cortex and limbic system, which are responsible for mood regulation, decision-making, and impulse control. Neuroimaging studies have shown abnormalities in these brain regions in individuals with bipolar disorder. Additionally, neurotransmitter imbalances, particularly involving serotonin, dopamine, and norepinephrine, are implicated in the mood swings observed in bipolar disorder. These imbalances affect neural connectivity and communication, leading to the symptomatic extremes of mania and depression.
Diagnosis of bipolar disorder involves a thorough clinical evaluation, including a detailed medical and psychiatric history, assessment of symptoms, and, often, input from family members. Standardized questionnaires and rating scales can aid in the diagnostic process. It's crucial to distinguish bipolar disorder from other conditions that can cause mood swings, such as major depressive disorder, borderline personality disorder, and schizophrenia.
Treatment for bipolar disorder typically involves a combination of medication and psychotherapy. Mood stabilizers like lithium and anticonvulsants, as well as atypical antipsychotics, are commonly prescribed to manage mania and hypomania. Antidepressants may be used cautiously due to the risk of triggering manic episodes. Psychotherapy, particularly cognitive-behavioral therapy (CBT) and psychoeducation, helps individuals understand their condition, develop coping strategies, and adhere to treatment plans. Lifestyle modifications, such as regular sleep schedules and stress management techniques, are also important. In severe cases, electroconvulsive therapy (ECT) may be considered. Long-term, consistent treatment is essential for managing symptoms and improving quality of life.
"Bipolar Disorder (Manic Depression)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bipolar Disorder (Manic Depression) pipeline landscape is provided which includes the disease overview and Bipolar Disorder (Manic Depression) treatment guidelines. The assessment part of the report embraces, in depth Bipolar Disorder (Manic Depression) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bipolar Disorder (Manic Depression) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Bipolar Disorder (Manic Depression) Emerging Drugs Chapters
This segment of the Bipolar Disorder (Manic Depression) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bipolar Disorder (Manic Depression) Emerging Drugs
Azetukalner: Xenon Pharmaceuticals
Azetukalner (XEN1101) is a novel candidate being developed by Xenon Pharmaceuticals for the treatment of bipolar depression. Azetukalner is a potent and selective Kv7 potassium channel opener designed to modulate neuronal excitability and is being evaluated in neuropsychiatric disorders, including bipolar depression. Xenon Pharmaceuticals initiated the Phase III X-CEED program to evaluate azetukalner in patients with bipolar I or II depression. The program comprises randomized, double-blind, placebo-controlled studies evaluating azetukalner 20 mg once daily as monotherapy over a 6-week treatment period.
LB-102 is a once-daily, oral small molecule and a methylated derivative of amisulpride, designed to improve central nervous system exposure while retaining the pharmacological properties of amisulpride. It is a potent and selective antagonist of D2, D3, and 5-HT7 receptors, with the potential to address depressive symptoms as well as cognitive and residual symptoms associated with bipolar depression. In January 2026, LB Pharmaceuticals initiated the Phase II ILLUMINATE-1 trial to evaluate the efficacy and safety of LB-102 in patients with bipolar I depression.
ABX-002 (elunetirom) is a novel candidate being developed by Autobahn Therapeutics for the treatment of bipolar depression. ABX-002 is a potent, selective, orally administered thyroid hormone receptor beta (TRB) agonist designed to enhance the beneficial effects of thyroid hormone signaling in the central nervous system. In January 2025, Autobahn Therapeutics initiated a Phase II study evaluating ABX-002 as an adjunctive treatment in adults experiencing depressive episodes associated with bipolar disorder. The open-label study evaluates ABX-002 added to patients' existing treatment and incorporates clinical assessments and brain-imaging measures to investigate biological and clinical effects. The FDA subsequently granted Fast Track designation for ABX-002 as an adjunctive treatment for bipolar depression in May 2026.
Bipolar Disorder (Manic Depression): Therapeutic Assessment
This segment of the report provides insights about the different Bipolar Disorder (Manic Depression) drugs segregated based on following parameters that define the scope of the report, such as:
DelveInsight's report covers around 30+ products under different phases of clinical development like
Bipolar Disorder (Manic Depression) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Bipolar Disorder (Manic Depression): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bipolar Disorder (Manic Depression) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bipolar Disorder (Manic Depression) drugs.
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Bipolar Disorder (Manic Depression): Overview
Pipeline Therapeutics
Therapeutic Assessment
Bipolar Disorder (Manic Depression)- DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Azetukalner: Xenon Pharmaceuticals
Mid Stage Products (Phase II)
LB-102: LB pharmaceuticals
Early Stage Products (Phase I)
Drug Name: Company Name
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Bipolar Disorder (Manic Depression) Key Companies
Bipolar Disorder (Manic Depression) Key Products
Bipolar Disorder (Manic Depression)- Unmet Needs
Bipolar Disorder (Manic Depression)- Market Drivers and Barriers
Bipolar Disorder (Manic Depression)- Future Perspectives and Conclusion
Bipolar Disorder (Manic Depression) Analyst Views
Bipolar Disorder (Manic Depression) Key Companies